Vitamin and Unsaturated Fatty Acid Supplements in Healthy and Uveitis Human Subjects

NCT ID: NCT06491979

Last Updated: 2024-11-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-15

Study Completion Date

2024-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if dietary supplements containing vitamin and unsaturated fatty acid works to intervene T cell inflammatory factor expression in patients with uveitis and healthy subjects in adults.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Uveitis Autoimmune Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitamin A treatment

Group Type EXPERIMENTAL

Vitamin A treatment

Intervention Type DIETARY_SUPPLEMENT

Vitamin A, 32 microgram per kilograms (of body weight) per day, for three weeks

Monounsaturated fatty acid mixture

Group Type EXPERIMENTAL

Monounsaturated fatty acid mixture

Intervention Type DIETARY_SUPPLEMENT

Monounsaturated fatty acid mixture (mainly Omega-7, Omega-9), 47 milligrams per kilogram (of body weight) per day, for three weeks

Polyunsaturated fatty acid mixture

Group Type EXPERIMENTAL

Polyunsaturated fatty acid mixture

Intervention Type DIETARY_SUPPLEMENT

Polyunsaturated fatty acid mixture (mainly Omega-3, Omega-6), 6 milligrams per kilogram (of body weight) per day, for three weeks

Fatty acid mixture

Group Type EXPERIMENTAL

Fatty acid mixture

Intervention Type DIETARY_SUPPLEMENT

Fatty acid mixture (mainly saturated fatty acid, Omega-6, Omega-7, Omega-9), 83 milligrams per kilogram (of body weight) per day, for three weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin A treatment

Vitamin A, 32 microgram per kilograms (of body weight) per day, for three weeks

Intervention Type DIETARY_SUPPLEMENT

Monounsaturated fatty acid mixture

Monounsaturated fatty acid mixture (mainly Omega-7, Omega-9), 47 milligrams per kilogram (of body weight) per day, for three weeks

Intervention Type DIETARY_SUPPLEMENT

Polyunsaturated fatty acid mixture

Polyunsaturated fatty acid mixture (mainly Omega-3, Omega-6), 6 milligrams per kilogram (of body weight) per day, for three weeks

Intervention Type DIETARY_SUPPLEMENT

Fatty acid mixture

Fatty acid mixture (mainly saturated fatty acid, Omega-6, Omega-7, Omega-9), 83 milligrams per kilogram (of body weight) per day, for three weeks

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy or with uveitis volunteers age 19-65 years.

Exclusion Criteria

* abnormal blood glucose, blood pressure, blood lipids, or other systemic diseases should not participate in the study
Minimum Eligible Age

19 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tianjin Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xiaomin Zhang

Principal Investigator, MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tianjin Medical University Eye Hospital

Tianjin, Tianjin Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023KY-54

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of Lutein on Visual Function
NCT03113864 TERMINATED NA
Age-Related Eye Disease Study 2 (AREDS2)
NCT00345176 COMPLETED PHASE3
Effects of Lutein in Retinitis Pigmentosa
NCT00029289 COMPLETED PHASE1/PHASE2